규제 업데이트
2026년 9월 25일•1분 읽기
FDA Approves AstraZeneca ISOETHARINE Inhalation (ANDA089615)
The FDA approved ANDA089615 for ISOETHARINE HYDROCHLORIDE inhalation solution (0.125%) by AstraZeneca. The product is listed as discontinued.
규제 업데이트
2026년 9월 21일•1분 읽기
FDA Grants Accelerated Approval to AstraZeneca’s Oral SERD Etcamah for HR‑Positive/HER2‑Negative Breast Cancer
The US FDA approved AstraZeneca’s oral SERD camizestrant, branded Etcamah, for HR‑positive/HER2‑negative breast cancer patients with ESR1‑mutated ctDNA detected before radiographic progression, based on the Phase 3 SERENA‑6 trial.
규제 업데이트
2026년 9월 21일•1분 읽기
UK R&D rebate hike prompts AstraZeneca, Merck to pull investment plans
A year after the UK raised NHS rebate rates on new branded medicines to 31.3%, AstraZeneca and Merck withdrew planned R&D investments, citing a challenging innovation environment.
규제 업데이트
2026년 9월 18일•1분 읽기
FDA Grants Priority Approval for AstraZeneca's IMFINZI (Durvalumab) BLA761069
The FDA approved AstraZeneca’s IMFINZI (durvalumab) under BLA761069, with priority review for efficacy and ongoing labeling updates through 2026.
규제 업데이트
2026년 8월 27일•1분 읽기
AstraZeneca to Pay $34M to Settle Texas Medicaid Kickback Lawsuit
AstraZeneca agreed to pay $34 million to resolve a lawsuit alleging illegal kickbacks to induce Medicaid prescriptions in Texas.
1